Clinical trial · Interventional
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
NCT06871007CI-TRIAL-00086995enrolling by invitationPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Children | — | UNRESOLVED | — |
| Nivolumab | — | UNRESOLVED | — |
| Primary Mediastinal (Thymic) Large B-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- The only ARM consists of nivolumab combined with DA-EPOCH-R protocol
- description
- Children with PMLBL will receive standard chemotherapy (dose-adjusted EPOCH-R) combined with nivolumab 40 mg on Day 2
- interventionNames
- Drug: Nivolumab
Primary outcomes (1)
- measure
- Event free survival
- timeFrame
- 5 year
- description
- Kaplan-Meyer estimate
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 5 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age from 0 years to 17 years 11 months * Established on the basis of histological and immunohistochemical studies, the diagnosis of PMLBL (the presence of programmed death-ligand on tumor cells is not necessary) * Lack of specific therapy for lymphoma * Signed informed consent Exclusion Criteria: * Age \>18 * History of specific therapy for lymphomas. * Drug intolerance
References
Publications (0)
Data not yet available
No reference posted for this study.